The one number that dominates the rest is whether you have to remember it. Implant and hormonal IUD fail under 0.2% a year; the pill, patch, and ring run around 4.6%, almost all of that from missed doses. A 20-fold gap between set-and-forget and daily-attention methods 1.
The long-term picture is more encouraging than its reputation. Ever-users of combined pills have lower lifetime ovarian, endometrial, and colorectal cancer risk, no rise in overall cancer, and modestly lower all-cause mortality 2 3. Ovarian protection alone is about 20% lower per five years of use, holding three decades after you stop 4.
The risks are real but small in absolute terms, and they live almost entirely in the estrogen. A levonorgestrel pill adds about 4 extra clots per 10,000 women a year over a baseline of 2; pregnancy itself runs 29 5. Progestin-only methods carry essentially none of the clot, stroke, or estrogen-related risk 6.
The whole decision is three trade-offs: efficacy versus daily attention, estrogen versus none, and how you want your periods. Match yourself to a row.
The near-term change is your period; the long-term one you never feel.
- Weeks to months: lighter periods, less cramping, less PMS. On the 52 mg hormonal IUD many users stop bleeding entirely within a year. Acne clears on a combined pill in three to six months 7.
- Years: five years on a combined pill roughly halves ovarian cancer risk, and the protection holds three decades after stopping 4. You never notice the cancer that didn't happen, but the actuarial win is real.
The fine print — when to skip it, and what people get wrong
The combined pill, patch, and ring have a hard don't-do-this list built around clot and stroke risk. Progestin-only methods clear nearly all of it 8.
The pill doesn't cause weight gain (only the injection does) and doesn't harm fertility: ovulation returns within a cycle or two off pills, IUD, or implant, the injection being the outlier at 6 to 12 months 9. You don't need a "break"; the gap just risks pregnancy.
The mood signal is largest in teens and in the early months 10. If mood or libido drops and stays down, switch rather than ride it out; "give it three months" applies to bleeding, not mood 11. St John's wort and some prescriptions can drop a combined pill below protection, so clear new meds against your method.
- 1Winner B, Peipert JF, Zhao Q et al. (2012). Effectiveness of long-acting reversible contraception. New England Journal of Medicine. link
- 2Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC (2017). Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. American Journal of Obstetrics and Gynecology. link
- 3Hannaford PC, Iversen L, Macfarlane TV et al. (2010). Mortality among contraceptive pill users: cohort evidence from Royal College of General Practitioners' Oral Contraception Study. BMJ. link
- 4Collaborative Group on Epidemiological Studies of Ovarian Cancer (2008). Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women with ovarian cancer and 87,303 controls. The Lancet. link
- 5Lidegaard Ø, Nielsen LH, Skovlund CW et al. (2011). Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ. link
- 6Curtis KM, Tepper NK, Jatlaoui TC et al. (2016). U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. link
- 7Arowojolu AO, Gallo MF, Lopez LM, Grimes DA (2012). Combined oral contraceptive pills for treatment of acne. Cochrane Database of Systematic Reviews. link
- 8WHO (2015). Medical eligibility criteria for contraceptive use, 5th edition. link
- 9Kaunitz AM, Arias R, McClung M (2008). Bone density recovery after depot medroxyprogesterone acetate injectable contraception use. Contraception. link
- 10Skovlund CW, Mørch LS, Kessing LV, Lidegaard Ø (2016). Association of hormonal contraception with depression. JAMA Psychiatry. link
- 11Pastor Z, Holla K, Chmel R (2013). The influence of combined oral contraceptives on female sexual desire: a systematic review. The European Journal of Contraception and Reproductive Health Care. link
დაკავშირებული სახელმძღვანელოში (11)
- — For adenomyosis, the levonorgestrel IUD is first-line treatment, not just contraception.
- — Continuous hormonal contraception is a mainstay for controlling endometriosis pain.
- — Beyond birth control, the hormonal IUD and the pill are first-line treatments for heavy periods.
- — The combined pill is a workhorse for PCOS — it regulates cycles and calms the skin and hair symptoms.
- — Still fertile in your 40s? A low-dose pill can steady the erratic perimenopausal bleeding and hot flashes while you still need contraception.
- — Used continuously to suppress ovulation, hormonal contraception is a core PMDD treatment, not just birth control.
- — For fibroid-driven heavy bleeding, the hormonal IUD is often the simplest effective option.
- — St John's Wort speeds up how fast your body clears these hormones, which can quietly drop a pill's protection — a real cause of failure.
- — The same hormonal IUD that handles contraception can later serve as the progestin half of menopausal hormone therapy.
- — Going on or off a hormonal method reshapes your bleeding pattern — tracking it tells you what's normal for your method and what isn't.
- — Migraine with aura plus the combined pill multiplies stroke risk — the single most important question to settle here.
Hormonal Contraception
Under the US ACA contraceptive mandate, most insured users pay $0; uninsured generic COC ~$15-50/month; LARC $0-$1300 upfront, but a 5-8 year duration brings per-year cost below daily pills. Within reach for nearly all users with insurance.
Among the most-studied medication classes in human history. WHO and CDC Medical Eligibility Criteria pull from thousands of trials and cohort studies; Danish national cohorts span 8M+ woman-years; RCGP cohort followed 46,022 women for 44 years. Efficacy and cancer-protection data are settled.
Pill = ~30 seconds daily, with adherence the main failure point; patch = weekly; ring = monthly; DMPA = clinic visit every 3 months; LARC = single clinic insertion lasting 3-8 years. Plus an initial decision/prescription visit. Real but modest.
Substantial functional improvement for many users: 52 mg LNG-IUS reduces menstrual blood loss ~90% within 6 months; combined methods reduce dysmenorrhea, PMS symptoms, endometriosis pain, and PCOS-related hirsutism and cycle irregularity. ACOG endorses hormonal contraception as first-line for heavy menstrual bleeding and dysmenorrhea regardless of contraceptive need.
Combined oral contraceptives improve acne via ethinylestradiol's SHBG elevation (cutting free testosterone) and direct anti-androgen progestin effects; Cochrane review of 31 trials shows effect sizes comparable to topical retinoids within 3-6 months (Arowojolu et al. 2012). Effect is class-specific to combined methods, not progestin-only or LARC.
Collaborative reanalysis of 45 studies showed ~20% RR reduction per 5 years of COC use for ovarian cancer with protection persisting 30+ years (CollabOvarian 2008); RCGP 44-year follow-up found lower all-cause mortality and lower colorectal/endometrial/ovarian cancer in ever-users (Iversen et al. 2017, Hannaford et al. 2010). Net positive after accounting for small VTE/stroke and breast cancer increments.
Bidirectional. Skovlund Danish cohort (n=1M) found RR 1.23 for antidepressant initiation in adults, 1.8 in adolescents, with the strongest signal in the first 6 months (Skovlund et al. 2016); the 2018 follow-up found doubled suicide attempt risk. Conversely, suppression of cyclical progesterone provides genuine relief in PMDD and severe PMS. Net population signal is small and slightly unfavourable; subgroup effects are large in both directions.